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I Introduction
New psychoactive substances are a broad range of drugs 
that are not controlled by the 1961 and 1971 United 
Nations drug control conventions but may pose similar 
threats to public health. Many of them are traded as ‘legal’ 
replacements to established controlled drugs such as 
cannabis, heroin, cocaine and MDMA.
Over the last decade, there has been a large increase in 
these substances as globalisation and new technology 
have allowed production to shift from small-scale illicit 
laboratories in Europe to commercial chemical and 
pharmaceutical operations in China that are capable of 
making hundreds of different substances on an industrial 
scale. Once in Europe, they are sold openly in branded 
products advertised as ‘legal highs’, under the guise of 
being ‘research chemicals’, and as ‘food supplements’, in 
attempts to make these substances attractive to users. 
They are also sold on the illicit drug market, either under 
their own names or passed off as established controlled 
drugs to unsuspecting users. In parallel with the growth in 
the range of substances and products that are offered, the 
consumer base has also grown and includes recreational 
users, chronic and marginalised drug users, those who 
self-medicate, and people wanting to improve how they 
look or their performance at work or when studying. The 
growth in the market is also reflected in a large increase in 
the number of seizures reported by law enforcement as 
well as in poisonings.
For more than 20 years, a three-step legal framework of 
early warning, risk assessment and control measures has 
allowed Europe to rapidly identify and react to public 
health threats caused by new substances (Council of the 
European Union, 2005). The European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) is responsible for 
the first two steps in this system, namely operating the EU 
Early Warning System with Europol (the European Union 
agency for law enforcement cooperation) (see ‘EU Early 
Warning System’) and conducting risk assessments; while 
the European Commission, the Council of the European 
Union and the European Parliament are responsible for 
control measures. 
This is the second update from the EU Early Warning 
System. In these publications, the EMCDDA aims to 
provide some insights into what is happening with new 
psychoactive substances in Europe, based on data from 
the agency’s early warning and risk assessment activities. 
This issue covers the period from January 2016 until 
December 2017, with aggregated data on seizures 
reported by law enforcement limited to 2016 data. A focus 
of this publication is the new fentanils (which form the 
large majority of the new synthetic opioids that have been 
reported in Europe) and the synthetic cannabinoids. For 
the purpose of this report, the term ‘seizures’ means any 
encounters of new psychoactive substances by law 
enforcement, including seizures, samples recovered from 
crime scenes, and shipments detained for inspection.
Since the previous publication, in March 2015, there have 
been a number of major developments in Europe 
(EMCDDA, 2015). Some of these are encouraging. The 
number of new substances reported for the first time each 
year during 2016 and 2017 has fallen by around 40 % 
compared with 2015. Much of this is related to a decrease 
in the number of new synthetic cannabinoids and synthetic 
cathinones appearing each year. In part, this may reflect 
the results of sustained efforts to control new substances 
in Europe, including their open sale as ‘legal highs’ on the 
high street. Law enforcement operations in China leading 
to the closure of laboratories making these substances 
might be another reason.
The EU Early Warning System, operated by the 
EMCDDA and Europol, plays a central role in 
supporting national- and EU-level preparedness and 
responses to new psychoactive substances. In 
operation for the past 20 years, it comprises those 
two agencies, 30 national early warning systems 
across Europe, the European Medicines Agency and 
the European Commission. The national systems 
routinely report data, such as seizures of new 
psychoactive substances from police and customs as 
well as poisonings, to the EMCDDA. These data are 
then used both to identify emerging threats and as 
the basis of the EMCDDA’s risk assessment activities. 
The EMCDDA transmits essential and urgent 
technical information as well as risk communications 
(such as public health alerts) to the Early Warning 
System network by email. It also operates an 
information system called the European Database on 
New Drugs (EDND). The system offers round-the-
clock access to information on more than 670 new 
substances based on data reported by the network, 
identified by the EMCDDA through its additional 
monitoring systems, and reported by other partners. 
Learn more: http://www.emcdda.europa.eu/
activities/action-on-new-drugs
EU Early Warning System
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Other developments are less encouraging. The analysis 
presented here suggests that the availability of many new 
substances remains relatively high and, in places, stronger 
links are developing with the established illicit drug market. 
It also appears that there is increasing interest from crime 
groups in making new substances, such as synthetic 
cathinones, in Europe. Another major challenge in the last 
few years has been the large number of highly potent new 
substances that have appeared on the market. These pose 
a high risk of life-threatening poisoning to users and are 
capable of causing explosive outbreaks that can 
overwhelm local healthcare systems. In some 
circumstances, law enforcement and laboratory personnel 
may be at risk of poisoning from occupational exposure. 
These substances are also easier to conceal and smuggle, 
with a few grams sufficient to make many thousands of 
doses for the drug market. Given the globalised nature of 
the market, these substances can pose a serious cross-
border threat to health. Currently, two groups that 
particularly stand out in this respect are the new synthetic 
opioids (particularly the fentanils) and the synthetic 
cannabinoids.
During 2016-17 there was a large increase in the 
availability of new synthetic opioids in parts of Europe. 
While they appear to play a small role in the overall market, 
they are one of the fastest-growing groups monitored by 
the EMCDDA. These substances, most of which come 
from the highly potent fentanyl family, are of special 
concern to public health because they pose a high risk of 
life-threatening poisoning, as an overdose can quickly stop 
a person from breathing. This makes them especially 
dangerous to users, particularly as many will be unaware 
that they might be sold as heroin and other illicit opioids or 
even sold as falsified (fake) medicines. Here, we provide an 
overview of the current situation with new fentanils in 
Europe — which in 2016-17 were involved in more than 
250 deaths — as well as reviewing the key findings of the 
risk assessments conducted by the EMCDDA on five of 
them during 2017.
While the number of new synthetic cannabinoids reported 
each year is falling, they continue to be the largest group of 
substances monitored by the EMCDDA. Seizures reported 
by law enforcement also indicate that they continue to be 
available across much of Europe. These substances are no 
longer just touted as ‘legal’ replacements to cannabis, but 
have developed a reputation as powerful and cheap 
intoxicants among vulnerable groups, such as the 
homeless and prisoners, who use them for their 
‘mind-numbing’ effects. Over the last few years, there has 
been an increase in the number of deaths reported to the 
EMCDDA involving these substances. The reasons for the 
pronounced psychoactive effects and severe poisoning are 
not particularly well understood, but the high potency of 
the substances and the unintentionally high doses that 
users are exposed to are important factors. Here we take a 
look at these factors in more detail, as well as reviewing 
the key findings of the risk assessments conducted by 
the EMCDDA on five of these cannabinoids during 2016 
and 2017. 
This report also highlights how the EMCDDA is responding 
to these challenges by helping strengthen preparedness 
and responses at national and EU levels. New EU 
legislation that was adopted in November 2017 will also 
significantly support this work. Finally, we reflect on the 
overall conclusion of this analysis, which suggests that, 
while sustained growth of the market may not be 
inevitable, new substances are driving greater complexity 
into the drug situation; we also ask what this may mean for 
Europe, and highlight the central role that early warning 
systems can play in responding to this complex public 
health problem.
Seizures of new psychoactive substances in Europe 
that are reported by law enforcement agencies must 
be understood as minimum values, as data are drawn 
from case reports rather than monitoring systems. 
Reports are influenced by a range of factors such as 
increasing awareness of new substances, their 
changing legal status, law enforcement capacities 
and priorities, and the reporting practices of law 
enforcement agencies. For the purpose of this report, 
the term ‘seizures’ means any encounters of new 
psychoactive substances reported by law 
enforcement, including seizures, samples recovered 
from crime scenes, and shipments detained for 
inspection. 
Some seizures contain more than one active 
ingredient, therefore more than one identification can 
be made from a single seizure.
There have been changes in the methodology used to 
analyse seizures of new psychoactive substances, 
some of which have occurred since previous report. 
This has led to the revision of a number of estimates 
from previous years; hence the figures presented 
here may differ from those in the previous report.
Key methodological points
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I Overview of seizures, 2016-17
By the end of December 2017, the EMCDDA was 
monitoring more than 670 new substances that have 
appeared on Europe’s drug market over the past 20 years. 
This total includes 51 substances that were reported for 
the first time during 2017 (Figure 1), namely 13 opioids, 12 
cathinones, 10 cannabinoids, 4 phenethylamines, 3 
benzodiazepines, 2 tryptamines, 1 arylcyclohexylamine, 1 
arylalkylamine, 1 piperidine/pyrrolidine and 4 substances 
that do not belong to these other groups. This was the 
second year in a row when the number of new substances 
reported for the first time has decreased, from a high of 
around 100 substances in 2014 and 2015 to around 50 to 
60 substances per year (roughly one new substance every 
week). It also marked the first time when the new opioids 
were the single largest group of new substances to appear 
on the drug market in any one year — a position that has 
previously been dominated by the cannabinoids and 
cathinones. With 38 substances overall, 2017 saw the 
opioids become the fourth largest group of substances 
monitored, after synthetic cannabinoids (179 substances), 
cathinones (130) and phenethylamines (94) and not 
including the miscellaneous category ‘other substances’.
I  Seizures reported by law enforcement  during 2016
During 2016, more than 70 000 seizures of new 
substances, weighing 4.1 tonnes, were reported to the 
EMCDDA by law enforcement agencies from across 
Europe (Figure 2). While the number of seizures was 
similar to those reported in 2015, there was a drop of 
around 30 % in the quantities reported, mostly due to a dip 
in reports involving synthetic cannabinoids. Overall, 
seizures during 2016 were once again dominated by 
cannabinoids and cathinones, which, together, accounted 
for around 80 % of the total number and quantity of new 
substances reported during the year (Figure 2). Similarly to 
FIGURE 1
New psychoactive substances notified to the EU Early Warning System for the first time 2005-17: number per year (left) 
and total number per category (right)
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previous years, around half (approximately 360) of the new 
substances currently being monitored were detected in 
Europe during 2016. Among other problems, this increases 
the risk of them being sold either deliberately or 
accidentally as other drugs. Sometimes, such as when 
new fentanils are sold as heroin or as fake medicines, this 
can have fatal consequences.
The section below provides an overview of seizures reported 
for the synthetic cathinones, new benzodia zepines and 
some of the other groups of substances monitored by the 
EMCDDA. Data for the new opioids and synthetic 
cannabinoids are discussed in separate sections.
Synthetic cathinones
Reflecting their use as legal replacements for cocaine, 
amphetamine and other controlled stimulants, there were 
more than 23 000 seizures of synthetic cathinones 
reported from across Europe in 2016 (Figure 3). These 
account for almost one-third of the total number of 
seizures of new substances over the year, and amounted 
to almost 1.9 tonnes, making synthetic cathinones the 
most commonly seized new psychoactive substances by 
quantity in 2016. The EMCDDA is currently monitoring 130 
of these substances, including 14 that were reported for 
the first time in 2016 and 12 during 2017. Synthetic 
cathinones are generally found in powder form. The five 
FIGURE 2
Number and quantity of seizures of new psychoactive substance reported to the EU Early Warning System:  
trends and distribution by category in 2016
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most commonly seized cathinones in 2016 were alpha-
PVP, 4-chloromethcathinone, 3-chloromethcathinone, 
4-methyl-N,N-dimethylcathinone and 
3-methylmethcathinone. The top five cathinones detected 
in powders were 4-chloromethcathinone (890 kg), 
4-chloroethcathinone (247 kg), N-ethylhexedrone (186 kg), 
3-methylmethcathinone (126 kg) and mexedrone (50 kg). 
In recent years, there have been indications of increasing 
interest in making synthetic cathinones in Europe, 
including seizures of precursors, equipment and illicit 
laboratories used to make mephedrone (which is now 
under international control), as well as 
4-chloromethcathinone and 3-chloromethcathinone.
New benzodiazepines
Reflecting consumer demand, the market in new 
benzodiazepines appears to have grown over the past few 
years. The EMCDDA is currently monitoring 23 of these 
substances, including six that were reported for the first 
time in 2016 and three during 2017. While the overall 
number of seizures reported by law enforcement during 
2016 decreased compared with 2015, the quantity reported 
increased. More than half a million tablets containing new 
benzodiazepines such as diclazepam, etizolam, 
flubromazolam, flunitrazolam and fonazepam were reported 
during 2016 — which was about 70 % more than in 2015. 
Some of these new benzodiazepines were sold as tablets, 
capsules or powders under their own names. In other cases, 
they were used to make fake versions of commonly 
prescribed benzodiazepine medicines, such as diazepam 
and alprazolam, and sold directly on the illicit drug market.
Other substances
During 2016, there were increases in the quantities 
reported for some of the other groups of substances that 
are monitored by the EMCDDA, including arylcyclohexyl-
amines, indolalkylamines, and piperidines and pyrrolidines.
I  Synthetic opioids
With a total of 38 different opioids reported, the number of 
synthetic opioids has grown rapidly in Europe since the 
first substance was reported in 2009. In fact, most of 
these substances have been reported for the first time 
during the past two years, with 9 reported in 2016 and 13 
during 2017. Although they play a small overall role in 
Europe’s drug market, many of the new opioids are highly 
potent substances that pose a risk of life-threatening 
poisoning because an overdose can cause respiratory 
depression (slowing down of breathing), which can lead to 
respiratory arrest (stopping breathing) and death. The 
public health importance of this risk is reflected in the fact 
that most deaths involving illicit opioid use are caused by 
respiratory depression (White and Irvine, 1999). Of 
particular concern are the new fentanils. These substances 
currently dominate this group, with a total of 28 reported 
since they first appeared in 2012.
Reflecting their small share of the market as well as their 
high potency, new opioids accounted for only around 2 % 
of the total number of seizures of new substances and 
about 0.2 % of the total quantity reported to the EU Early 
Warning System during 2016. New opioids are found 
mainly in powders but also in tablets and, since 2014, 
liquids. For the most part, seizures are dominated by 
fentanils. There were around 1 600 seizures of new opioids 
reported by law enforcement during 2016, of which 70 % 
were related to fentanils. These included 7.7 kg of powders 
(of which 60 % contained fentanils), approximately 23 000 
tablets (of which 13 % contained fentanils) and 4.5 litres of 
liquids (of which fentanils accounted for 96 % of the total). 
Some of these liquids are from seizures made by police 
and customs of nasal sprays, which appear to be growing 
in popularity as a way of using these substances.
FIGURE 3
Seizures of synthetic cathinones reported to the EU Early 
Warning System: trends in number of seizures and 
quantity detected, 2005-16
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I  Fentanils: background
During the 1960s, attempts to develop better and safer 
analgesic medicines led to the synthesis and testing of a 
series of new opioid narcotic analgesic drugs by the 
pharmaceutical company Janssen Pharmaceutica. 
Fentanyl was the first substance in this highly potent 
family to be synthesised and was followed by a series of 
related substances, which together are known as the 
fentanils (Janssen, 1982; Janssen and Van der Eycken, 
1968). Since then, dozens more of these substances have 
been synthesised and tested by scientists. A small number 
— fentanyl, alfentanil, sufentanil and remifentanil — have 
become widely used in human medicine in anaesthesia 
and for pain management, while some are used in veterinary 
medicine in anaesthesia and for pain management, and, in 
the case of carfentanil and thiafentanil, to immobilise large 
animals. Some of the fentanils are also used to study how 
the body works, provide insights into disease and help 
develop new medicines (Ujváry et al., 2017).
Like other types of opioid analgesics, such as morphine 
and heroin, the fentanils produce their main effects by 
activating a receptor in the brain called the mu-opioid 
receptor (Cox, 2011; Pasternak and Pan, 2013; Ujváry et al., 
2017). The effects include euphoria, relaxation, analgesia, 
sedation, slowing of the heart, hypothermia and respiratory 
depression (Cox, 2011; Dahan et al., 2001; Kieffer, 1999; 
Pattinson, 2008; Romberg et al., 2003). It is this last effect 
that poses the greatest danger to users, as, because of the 
high potency of these substances, small amounts can 
cause severe, life-threatening poisoning from respiratory 
depression. Left untreated, this can be fatal (Cox, 2011; 
Dahan et al., 2010; Pattinson, 2008; Somerville et al., 2017; 
White and Irvine, 1999). Fentanils also have an abuse 
liability and dependence potential. In recognition of their 
potential to cause these serious harms, 21 fentanils are 
controlled by the United Nations international drug control 
system (1).
Timely administration of the antidote naloxone can rapidly 
reverse the severe respiratory depression caused by 
fentanils (Kim and Nelson, 2015). Of note is that recent 
experiences in the United States and Canada suggest 
that, compared with treating heroin overdoses, larger and 
(1) A total of 21 fentanils are controlled under the United Nations Single 
Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol. 
These are 3-methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-
methylfentanyl, alpha-methylfentanyl, alpha-methylthiofentanyl, beta-
hydroxy-3-methylfentanyl, beta-hydroxyfentanyl, para-fluorofentanyl, 
thiofentanyl, acetylfentanyl and carfentanil, which are controlled under 
Schedules I and IV; and alfentanil, fentanyl, sufentanil, remifentanil, 
butyrfentanyl, ocfentanil, furanylfentanyl, acryloylfentanyl, 
4-fluoroisobutyrfentanyl and tetrahydrofuranylfental, controlled under 
Schedule I.
additional doses of naloxone have been required in some 
cases in order to reverse the respiratory depression (Faul 
et al., 2017; Klar et al., 2016; Somerville et al., 2017; Sutter 
et al., 2017). While this finding needs further study, it 
could be due to factors such as the high potency of the 
fentanils, the dose an individual is exposed to and the fact 
that the effects of these substances may last longer in the 
body than those of naloxone. Patients who have 
overdosed with fentanils may need longer periods of 
observation after initial treatment in case respiratory 
depression reoccurs.
Alongside their legitimate uses as medicines and in 
research, the fentanils also have a long history of illicit use 
as replacements for heroin and other controlled opioids. 
Between 1979 and 1988, more than 10 fentanils that had 
been made in illicit laboratories were detected on the drug 
market in the United States (Henderson, 1991). The first 
was alpha-methylfentanyl, followed by substances such as 
3-methylfentanyl and 4-fluorofentanyl. Typically, they were 
sold as heroin or ‘synthetic heroin’. Together, these 
substances were involved in more than 100 deaths, mostly 
in the state of California. Later, in the mid-2000s, illicitly 
manufactured fentanyl was sold as heroin or in mixtures 
with heroin, and was responsible for outbreaks of 
overdoses that involved hundreds of deaths in the eastern 
United States (Schumann et al., 2008). It appears that, 
with the exception of Estonia, where 3-methylfentanyl and 
fentanyl were responsible for an epidemic of fatal 
poisonings during this time, these substances caused 
limited problems elsewhere in Europe (Berens et al., 1996; 
de Boer et al., 2003; Fritschi and Klein, 1995; Kronstrand et 
al., 1997; Ojanperä et al., 2008; Poortman-van der Meer 
and Huizer, 1996).
Over the past few years, there has been a large increase in 
the availability of fentanils in the United States, Canada 
and Europe (Gladden et al., 2016; US CDC, 2015). This has 
been driven by the opioid epidemics in North America, 
interest in selling these substances in Europe and broader 
changes in the illicit drug market.
Situation in Europe
Since 2012, a total of 28 new fentanils have been 
identified on Europe’s drug market. This includes eight 
substances that were reported for the first time in 2016 
and 10 during 2017. During this period, there has also been 
a large increase in seizures reported by customs at 
international borders and police at street-level (Figure 4) 
(see also ‘Reducing the risk of occupational exposure to 
fentanils’, page 11). While the picture differs widely 
across Europe, 23 countries have reported detections of 
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one or more of these substances (Figure 5) (2). Reports to 
the EMCDDA of fatal poisonings have also increased 
substantially from some countries (EMCDDA, 2016a; 
EMCDDA, 2017a,b,c,d,e,f,g; EMCDDA, 2018a,b).
It appears that most shipments of new fentanils coming 
into Europe originate from companies based in China. 
Production in illicit laboratories, including in Europe, has 
also been reported occasionally. Typically, production of 
fentanyl and other fentanils is relatively straightforward, 
which adds to the challenges in responding to these 
substances.
Like other new substances, one of the reasons behind the 
increase in these fentanils is that they are not controlled 
under the United Nations drug control conventions. This 
means that in many countries they can be manufactured 
and traded relatively freely and openly — a situation which 
has been exploited by entrepreneurs and crime groups 
using companies based in China to make the substances. 
The fentanils are typically shipped to Europe by express 
mail services and courier services. From here, they are 
then sold as ‘legal’ replacements for illicit opioids on the 
surface web and on the darknet. Unknown to users, they 
are also sold as heroin or mixed with heroin and other illicit 
opioids. Occasionally they have also been used to make 
fake medicines and, less commonly, sold as cocaine (see 
‘Fentanils in fake medicines and cocaine’, page 12).
Fentanils have been found in a variety of physical and 
dosage forms in Europe. The most common form is 
powders, but they have also been detected in liquids and 
tablets. Depending on the circumstances, seizures of 
powders have ranged from milligram to kilogram 
quantities. They may be relatively pure, especially when 
seized coming into the European Union. They may also be 
mixed with one or more substances. In the latter case, 
these include commonly used cutting agents (such as 
mannitol, lactose and paracetamol), as well as heroin and 
other fentanils/opioids. To a much smaller degree, other 
drugs, such as cocaine and other stimulants, have also 
been detected in mixtures with fentanils in Europe. During 
2016, more than 4.6 kg of powder containing fentanils was 
reported, while almost 4.5 litres of liquid and around 2 900 
tablets were also reported. Less commonly, fentanils have 
also been found in blotters and plant material. In these 
cases, there may be no indication that they contain 
(2) Austria, Belgium, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Hungary, Ireland, Latvia, Lithuania, Luxembourg, the 
Netherlands, Poland, Portugal, Slovenia, Spain, Sweden, the United Kingdom 
and Norway have all reported one or more detections of new fentanils that 
have been formally notified as new psychoactive substances under the terms 
of Council Decision 2005/387/JHA.
FIGURE 4
Seizures of fentanils reported to the EU Early Warning 
System: trends in number of seizures and quantity 
detected, 2012-16
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fentanils, which could pose a risk of poisoning to people 
who use them.
During 2016, the top five fentanils detected in powders 
reported by law enforcement were valerylfentanyl 
(0.98 kg), ocfentanil (0.70 kg), carfentanil (0.57 kg), 
4-fluoro-isobutyrylfentanyl (0.52 kg) and furanylfentanyl 
(0.47 kg). The top five fentanils detected in liquids were 
acryloylfentanyl (2.23 l), furanylfentanyl (1.41 l), 
tetrahydro furanylfentanyl (0.50 l), 4-fluoro-isobutyryl-
fentanyl (0.21 l) and cyclopentylfentanyl (0.06 l). The 
fentanils detected in tablets during 2016 were 
acryloylfentanyl (1 451 tablets), 4-fluoro-isobutyrylfentanyl 
(1 155), acetylfentanyl (150), cyclopentylfentanyl (105) 
and furanylfentanyl (45).
Fentanils are sold and used as ‘legal’ substitutes for illicit 
opioids and prescription opioid medicines; this may 
include for self-medication, such as treating pain and/or 
opioid withdrawal. In addition, they are also sold as or in 
mixtures with heroin and other illicit opioids. Information 
from law enforcement and death investigations in Europe 
have found that fentanils are used by vulnerable and 
marginalised opioid users, including those who inject 
heroin and other illicit opioids. In many cases, these 
individuals will not be aware that they are using them. This 
can place them at greater risk of life-threatening overdose. 
Other groups who may use fentanils include those who are 
experimenting with the substance (such as psychonauts).
While fentanils are often injected, their high potency and 
ease of use mean that nasal sprays containing diluted 
solutions have become an increasingly common way of 
using these substances in some parts of Europe in recent 
years. Unlabelled nasal sprays containing acryloylfentanyl, 
offered for sale online, were detected in Sweden in 2016 
(Figure 6). This substance was involved in 47 deaths in 
Europe during 2016. E-liquids containing fentanils that can 
be vaped using electronic cigarettes have also been 
reported. Compared with injecting, these make it easier for 
people to use fentanils while still giving them a similar 
FIGURE 5
Number of different fentanils detected by country reported 
to the EU Early Warning System, 2012-17 
Given the increase in availability of fentanils in 
Europe, the issue has been raised that first 
responders, law enforcement and laboratory 
personnel may encounter them as part of their work. 
Law enforcement officers could encounter fentanils 
in a range of operational settings. These could 
include consignments in transit, for example vehicles 
(such as aircraft and courier vans), ports of entry 
(which may include courier and mail centres), illicit 
laboratories, storage/processing/distribution 
facilities (such as sites where vendors re-package 
into smaller quantities for onward sale), tableting and 
nasal spray/e-liquid production facilities, sites used 
to mix fentanils with heroin/illicit opioids, and at 
street level. Fentanils may also be encountered during 
the transport, processing, forensic investigation, 
storage and disposal of seized materials. As a result, 
there could be a potential risk to personnel from 
occupational exposure, which may need to be risk 
assessed. With appropriate measures — protocols 
and procedures, equipment and training — fentanils 
can be handled safely. For further information on this 
issue, including assessing and responding to such 
scenarios, agencies may wish to refer to 
‘Recommendations on selection and use of personal 
protective equipment and decontamination products 
for first responders against exposure hazards to 
synthetic opioids, including fentanyl and fentanyl 
analogues’, published by the United States 
InterAgency Board for Equipment Standardization 
and Interoperability (2017), as well as ‘Fentanyl 
safety recommendations for first responders’, 
published by the White House National Security 
Council (2017).
Reducing the risk of occupational 
exposure to fentanils
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psychoactive effect. Their use may also pose a high risk of 
accidental overdose. Nasal sprays and e-liquids could 
make using fentanils more attractive and socially 
acceptable, helping them spread more widely.
Since late 2015, the EMCDDA has conducted eight joint 
investigations with Europol on fentanils that have caused 
serious concern at European level. The two agencies 
investigated acetylfentanyl in 2015, acryloylfentanyl and 
furanylfentanyl in 2016, and 4-fluoroisobutyrylfentanyl 
(4F-iBF), tetrahydrofuranylfentanyl (THF-F), carfentanil 
(see ‘Carfentanil in Europe’, page 16), methoxyacetyl-
fentanyl and cyclopropylfentanyl during 2017. Together, 
these substances have been involved in more than 250 
deaths, many of which were attributed directly to these 
substances. Five of these substances were formally risk 
assessed by the EMCDDA during 2017 (Table 1), and 
methoxyacetylfentanyl and cyclopropyl fentanyl were 
assessed early in 2018. So far, acryloyl fentanyl and 
furanylfentanyl have been subject to control measures at 
EU level because of the risks they pose to Europe.
I  Synthetic cannabinoids
I  Background
Synthetic cannabinoids, also known as synthetic 
cannabinoid receptor agonists, are a group of drugs that 
mimic the effects of a substance found in cannabis called 
tetrahydrocannabinol (THC). THC is responsible for many 
Recently, there has been a large increase in the number 
of seizures by police in the United States and Canada of 
fake medicines containing fentanils. These fakes are 
sold directly on the illicit drug market as commonly used 
opioid analgesics (pain killers) and benzodiazepines. At 
the same time, there has also been an increase in 
reports of fentanils being mixed with or sold as cocaine. 
As users are unaware of this, it can increase the risk of 
life-threatening overdose. A number of mass poisonings 
have been reported in North America due to this type of 
adulteration (Arens et al., 2016; Klar et al., 2016; Sutter 
et al., 2017; Tomassoni et al., 2017). Those at particularly 
high risk include users who may not have any tolerance 
to opioids, such as cocaine users. While similar reports 
have been comparatively rare so far in Europe, a number 
of seizures have been reported since 2016. This 
includes recent seizures by police in Sweden of fake 
Xanax benzodiazepine tablets that contained 
cyclopropylfentanyl, a substance that was involved in 
more than 80 deaths in Europe during 2017.
Fake Xanax tablets  
 
Copyright: Swedish Police.
Fentanils in fake medicines and cocaine
Source: Image kindly provided by Prof Anders Helander, 
Department of Laboratory Medicine, Karolinska Institutet, 
Stockholm, Sweden. Copyright: Anders Helander.
FIGURE 6
Unlabelled nasal sprays containing acryloylfentanyl that 
were sold online in Sweden in 2016
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of the psychoactive effects of cannabis which give that 
feeling of being ‘stoned’ or ‘high’ (Gaoni and Mechoulam, 
1964; Huestis et al., 2001; Pertwee, 2005a; Pertwee, 
2014). These effects are caused by activating a receptor in 
the brain called the cannabinoid receptor type 1 (CB1 
receptor) (Huestis et al., 2001; Pertwee, 2014). The 
receptor is part of a signalling system in the body called 
the endocannabinoid system, which helps regulate, among 
other things, behaviour, mood, pain, appetite, sleep and 
the immune system (Pertwee, 2015).
Similar to the fentanils, the synthetic cannabinoids were 
originally developed by scientists to study the body, 
provide insights into disease and help develop new 
medicines (Pertwee, 2005b; Reggio, 2009). Around the 
mid-2000s, they began to appear in Europe in products 
called ‘Spice’ that were sold as ‘legal’ replacements to 
cannabis. In these products, powders containing synthetic 
cannabinoids were mixed with plant material which could 
then be smoked as cigarettes (‘joints’) (Auwärter et al., 
2009; EMCDDA, 2009; Jack, 2009). Since then, 179 
cannabinoids have been identified on the drug market in 
hundreds of different products (Figure 7). The products are 
commonly referred to as ‘herbal smoking mixtures’, ‘Spice’, 
‘K2’, ‘synthetic cannabis’ and ‘synthetic marijuana’. Most of 
the synthetic cannabinoid powders are made in China, 
with the final products made in Europe. 
Because synthetic cannabinoids work in a similar way to 
THC, many of their effects are similar to those of cannabis 
(Auwärter et al., 2009). Most prominently, they are able to 
create the feeling of being ‘stoned’. This includes 
Common name Acryloylfentanyl Furanylfentanyl 4F-iBF THF-F Carfentanil
Chemical name N-(1-Phenethyl- 
piperidin-4-yl)- 
N-phenylacryl- 
amide
N-Phenyl-N-[1-(2-
phenylethyl)
piperidin-4-yl]
furan-2-carbox-
amide
N-(4-Fluoro- 
phenyl)-N-(1-
phenethylpiperi-
din-4-yl)isobutyr -
amide
N-Phenyl-N- 
[1-(2-phenyl- 
ethyl)piper-idin- 
4-yl]oxol-ane-2- 
carboxamide
Methyl 1-(2-pheny-
lethyl)-4-[phe-
nyl(propanoyl)
amino]piperi-
dine-4-carboxylate
Chemical structure
Category Synthetic opioid Synthetic opioid Synthetic opioid Synthetic opioid Synthetic opioid
Pharmacology μ-opioid receptor 
agonist
μ-opioid receptor 
agonist
μ-opioid receptor 
agonist
μ-opioid receptor 
agonist
μ-opioid receptor 
agonist
Formal notification to 
the EU Early Warning 
System
7 July 2016 3 November 2015 26 August 2016 23 December 2016 12 February 2013
Number of deaths 47 23 20 14 61
Number of countries 
where associated 
deaths occurred
3 6 2 1 8
Number of seizures 
by law enforcement
162 143 24 53 801
Number of countries 
where it has been 
seized
5 14 4 1 7
Total quantity seized 113 g powder
1 495 ml liquid
896 tablets
1 036 g powder
6 g plant material
1 559 ml liquid
45 tablets
379 g powder
208 ml liquid
6 727 tablets 
99 g powder
950 ml liquid
3.3 kg powder
TABLE 1
Key findings of the risk assessments of acryloylfentanyl, furanylfentanyl, 4-fluoroisobutyrylfentanyl (4F-iBF), 
tetrahydrofuranylfentanyl (THF-F) and carfentanil conducted by the EMCDDA
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relaxation, euphoria, lethargy, depersonalisation, distorted 
perception of time, impaired motor performance, 
hallucinations, paranoia, confusion, fear, anxiety, dry 
mouth, bloodshot eyes, tachycardia (an abnormally fast 
heart rate), nausea and vomiting. In some cases, these 
effects appear to be much more pronounced and severe 
than those produced by cannabis (Ford et al., 2017; 
Zaurova et al., 2016).
I  Situation in Europe
Synthetic cannabinoids are the largest group of substances 
that are monitored by the EU Early Warning System. In 
2016-17, there was a marked decrease in the number of 
new cannabinoids reported for the first time. Despite this, 
the cannabinoids were the most frequently seized new 
psychoactive substances in 2016, with just over 32 000 
reports (Figure 8). This is an increase of almost 10 000 on 
the previous year and accounts for nearly half the total 
number of seizures of new psychoactive substances 
reported in 2016. Almost 1.5 tonnes of the substances 
were reported during 2016. Of this, almost 40 % was in the 
form of plant material (smoking mixtures), with powders 
accounting for almost another 13 %. Seizures in Europe of 
synthetic cannabinoids in powder form together with other 
raw ingredients, and of processing facilities, demonstrate 
that smoking mixtures are made in Europe. When made 
into ‘smoking mixtures’, the amount of powder that was 
reported in 2016 could have been used to make many 
millions of doses. Of note is that there has been a marked 
drop in the amount of seizures reported by law enforcement of 
synthetic cannabinoids in powder form, from a high of 
almost 600 kg in 2013 to around 190 kg in 2016 (Figure 8). 
The reasons for this 70 % drop are unclear, but it might 
signal a decrease in the production of smoking mixtures in 
Europe in the past few years as laws have been tightened.
The five most commonly seized synthetic cannabinoids 
reported by law enforcement in 2016 were 
MDMB-CHMICA, AB-CHMINACA, UR-144, 5F-AKB48 and 
AMB-FUBINACA. The top five cannabinoids seized in plant 
material (smoking mixtures) were AB-FUBINACA (361 kg), 
5F-AMB-PINACA (116 kg), AMB-FUBINACA (20 kg), 
5F-MDMB-PINACA (15 kg) and AB-CHMINACA (13 kg), 
while the top five cannabinoids seized in powders were 
5F-NAPICA (AM-6527 5-fluoropentyl derivative) (54 kg), 
CUMYL-4CN-BINACA (50 kg), AMB-FUBINACA (27 kg), 
5F-MDMB-PINACA (15 kg) and AB-FUBINACA (7 kg).
Data reported to the EMCDDA through the EU Early 
Warning System as well as other sources suggest that 
severe and fatal poisoning is much more common with 
synthetic cannabinoids than with cannabis (EMCDDA, 
2016c; EMCDDA, 2017h,i,j,k,l; Tait et al., 2016; Winstock 
Source: Image kindly provided by Dr Jan Schäper, Bayerisches 
Landeskriminalamt, Munich, Germany. Copyright: Jan Schäper.
FIGURE 7
Products containing CUMYL-PeGACLONE, a synthetic 
cannabinoid, seized in Germany in 2016 
FIGURE 8
Seizures of synthetic cannabinoids reported to the EU 
Early Warning System: trends in number of seizures and 
quantity seized, 2005-16
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and Barratt, 2013; Zaurova et al., 2016). The reasons for 
the more pronounced psychoactive effects and severe and 
fatal poisoning seen with synthetic cannabinoids are not 
particularly well understood, but at least two factors are 
likely to be important: the high potency of the substances 
and the unintentionally high doses that users are 
exposed to.
Firstly, studies have found that many of the cannabinoids 
sold on the drug market are much more potent than THC 
(behaving as so-called ‘full agonists’). This means that 
even at very small doses they can activate the CB1 
receptor much more strongly than THC (Banister et al., 
2016; Ford et al., 2017; Longworth et al., 2017a,b; Reggio, 
2009; Tai and Fantegrossi, 2017). It is worth noting that 
little is known about the effects of synthetic cannabinoids 
on other signalling systems in the body, which may also 
explain some of the effects of these substances.
Secondly, the process for mixing the synthetic 
cannabinoids with the plant material to make smoking 
mixtures (which are the most common way of using these 
substances) can lead to dangerous amounts of the 
substances in the products. This is because producers 
have to guess the amount of cannabinoids to add, while 
the mixing process makes it difficult to dilute the 
cannabinoids sufficiently and distribute them consistently 
throughout the plant material. This can result both in 
products that contain toxic amounts of the substances in 
general, as well as in products where the cannabinoids are 
clumped together, forming highly concentrated pockets 
among the plant material (Figure 9) (Ernst et al., 2017; 
Frinculescu et al., 2017; Langer et al., 2014, 2016; 
Moosmann et al., 2015; Schäper, 2016). These issues are 
made worse because the products are smoked (or vaped), 
allowing the substances to be rapidly absorbed into the 
bloodstream and to reach the brain, where they cause 
many of their effects.
The combination of these two factors makes it difficult for 
users to control the dose that they are exposed to. This can 
lead them to unintentionally administer a toxic dose (see 
‘Other risks related to synthetic cannabinoids and smoking 
mixtures’, page 18). Accounts from patients and people 
who witness poisonings suggest that in some cases a 
small number of puffs from a joint have been sufficient to 
cause severe and fatal poisoning.
These factors are also responsible for outbreaks of mass 
poisonings caused by smoking mixtures. These have 
ranged in size from a handful of victims to over 800 people, 
some of whom have died. Such outbreaks can also rapidly 
overwhelm the capacity of emergency responders and 
other parts of local healthcare systems (such as hospital 
emergency departments). Many of the outbreaks that have 
been reported so far are from the United States, but they 
have also occurred in Russia and Europe (Adams et al., 
2017; Kasper et al., 2015; Schwartz et al., 2015; Shevyrin et 
al., 2015; Springer et al., 2016; Trecki et al., 2015; Tyndall et 
al., 2015).
While the poisoning caused by synthetic cannabinoids can 
be similar to that caused by cannabis, severe effects are 
also commonly reported. These include serious 
cardiovascular toxicity (including sudden death), rapid loss 
of consciousness/coma, respiratory depression, seizures 
and convulsions, hyperemesis, delirium, agitation, 
psychosis, and aggressive and violent behaviour (Adams et 
al., 2017; Bäckberg et al., 2017; Hill et al., 2016; Kasper et 
al., 2015; Schwartz et al., 2015; Shevyrin et al., 2015; 
Springer et al., 2016; Trecki et al., 2015; Tyndall et al., 2015; 
Waugh et al., 2016).
In addition, the effects of poisoning — particularly loss of 
consciousness, respiratory depression and behavioural 
effects — may place users at additional risk. This includes 
choking on/inhaling vomit, drowning, falling, hypothermia 
as a result of falling unconscious outside in cold weather, 
and self-inflicted violence/injury (Tait et al., 2016; Yeter, 
FIGURE 9
Uneven distribution of cannabinoid in a herbal mixture 
seized by German police in 2014
Note: This product contained MDMB-CHMICA, a synthetic 
cannabinoid that was linked to more than 28 deaths in Europe 
between 2014 and 2016. Large white lumps of MDMB-CHMICA 
can be seen at the bottom left of the image. Given the high 
potency of MDMB-CHMICA, such large amounts pose a risk of 
severe and even fatal poisoning to users. 
Source: Originally published by Schäper (2016, p. 112). 
Image kindly provided by Dr Jan Schäper, Bayerisches 
Landeskriminalamt, Munich, Germany. Copyright: Jan Schäper.
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2017). The aggressive and violent behaviours reported 
with synthetic cannabinoids may also place others at risk 
of injury. Driving while under the influence of synthetic 
cannabinoids places users and others at risk of injury 
(Capron, 2016; Kaneko, 2017; Karinen et al., 2015; 
Musshoff et al., 2014).
People who use synthetic cannabinoids include 
recreational users (including cannabis users), high-risk 
drug users and groups who experiment with the 
substances (such as psychonauts). This may also include 
individuals who are subject to drug testing (such as people 
in drug treatment, prisoners and drivers) because some 
drug tests/screens cannot detect some of the 
cannabinoids; this may be especially the case with those 
substances that are relatively new to the drug market. Of 
particular concern is that synthetic cannabinoids are 
increasingly used by vulnerable groups, such as the 
homeless and prisoners, in some areas. In at least some 
cases, these users are specifically seeking out these 
substances because they have a reputation for causing 
profound intoxication at relatively low cost. Reports 
suggest that this has exacerbated existing health and 
social problems as well as creating new ones for these 
groups. For example, in prisons, alongside the adverse 
health effects, the market in synthetic cannabinoids has 
been linked to an increase in aggression, violence, bullying 
and debt. In some cases, this has caused a serious threat 
to the overall safety and security of the prison environment 
(Blackman and Bradley, 2017; HMIP, 2015; Ralphs et al., 
2017; User Voice, 2016).
Since 2016, the EMCDDA has conducted five joint 
investigations with Europol on synthetic cannabinoids that 
have caused serious concern at European level. The two 
agencies investigated MDMB-CHMICA in 2016, and 
AB-CHMINACA, ADB-CHMINACA, 5F-MDMB-PINACA and 
CUMYL-4CN-BINACA during 2017. Together, these 
Carfentanil is one of the most potent fentanils 
developed by scientists (Janssen, 1982). It is used in 
research and, in some countries, as a veterinary 
medicine to immobilise large animals. The substance 
was first detected in Europe in December 2012 in a 
seizure made by police in Latvia. Until 2016, detections 
were limited to Latvia, Lithuania and Estonia. During 
2017, there was a spike in reports of these substances 
from law enforcement as well from death investigations 
in parts of Europe. This led to a joint investigation by the 
EMCDDA and Europol in May 2017 and risk assessment 
later in the year. These found that during 2017 there had 
been a rapid increase in the availability of carfentanil in 
Europe. Overall, seizures were reported in seven 
countries. This increase was thought to be linked to 
supply by companies based in China, with sales of 
wholesale and consumer amounts on the surface web 
and the darknet helping the substance to spread. 
Law enforcement agencies have reported more than 
800 seizures of carfentanil to the EMCDDA since 
January 2013, with around 25 % of these seizures 
occurring in the first four months of 2017. Overall, in 
almost 50 % of these cases, carfentanil was detected in 
mixtures with heroin and/or another opioid. In at least 
three countries, carfentanil was in the heroin/illicit 
opioid supply chain. In one case, more than 400 g of 
carfentanil was seized by police, which would probably 
have been sufficient to produce millions of doses for the 
drug market. Between November 2016 and April 2017, 
carfentanil was involved in at least 61 deaths in eight 
countries. In many cases, those who died were people 
who used heroin.
 
Carfentanil seized in Norway
Note: Foil packet containing a ziplock bag labelled ‘C.50’ that 
contained carfentanil as a white powder. It was bought on a 
darknet market and recovered from a scene of death in Norway 
in 2017. Image kindly provided by Norwegian National Criminal 
Investigation Service (Kripos). Copyright: Norwegian National 
Criminal Investigation Service (Kripos).
Carfentanil in Europe
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substances have been involved in more than 100 deaths, 
many of which were attributed directly to these 
substances. All five of these substances were formally risk 
assessed by the EMCDDA during either 2016 or 2017 
(Table 2). So far, MDMB-CHMICA has been subject to 
control measures at EU level because of the risks it poses 
to Europe.
Common name MDMB-CHMICA AB-CHMINACA ADB-CHMINACA
5F-MDMB-
PINACA
CUMYL-4CN-
BINACA
Chemical name Methyl 2-[[1- 
(cyclohexyl-
methyl)-1H-in-
dole-3-carbonyl]
amino]-3,3-di-
methylbutanoate
N-(1-Amino-3- 
methyl-1-oxobu-
tan-2-yl)-1-(cy-
clohexylmethyl)- 
1H-indazole-3- 
carboxamide
N-(1-Amino-3,3-
dimethyl-1-oxo- 
butan-2-yl)-1-(cy-
clohexylmethyl)- 
1H-indazole-3-
carboxamide
Methyl 2-{[1-(5-
fluoropentyl)-
1H-indazole-3-
carbonyl]
amino}-3,3-di-
methylbutanoate
1-(4-Cyano- 
butyl)-N-(2-phe-
nylpropan-2-yl)-
1H-indazole-3-
carboxamide
Chemical structure
Category Synthetic 
cannabinoid
Synthetic 
cannabinoid
Synthetic 
cannabinoid
Synthetic 
cannabinoid
Synthetic 
cannabinoid
Pharmacology Full agonist at the 
CB
1
 receptor; 
agonist at the CB
2
 
receptor
Full agonist at the 
CB
1
 receptor; 
partial agonist at 
the CB
2
 receptor
Full agonist at the 
CB
1
 receptor; 
agonist at the CB
2
 
receptor
Full agonist at the 
CB
1
 and CB
2
 
receptors
Full agonist at the 
CB
1
 and CB
2
 
receptors
Formal notification to the EU 
Early Warning System
12 September 
2014
10 April 2014 24 September 
2014
8 January 2015 4 March 2016
Number of deaths 29 31 13 28 11
Number of countries where 
associated deaths occurred
6 6 3 2 2
Number of seizures by law 
enforcement
>3 600 6 422 3 794 1 986 2 461
Number of countries where it 
has been seized
25 26 19 27 12
Total quantity seized 67 kg plant 
material
46 kg powder
190 kg plant 
material
44 kg powder
293 ml liquid
194 g blotters
139 kg plant 
material
10 kg powder
25.5 g blotters
100 kg plant 
material
13 kg powder
309 g and 94 ml 
liquid
blotters
261 kg plant 
material
52 kg powder
blotters
TABLE 2
Key findings of the risk assessments of MDMB-CHMICA, AB-CHMINACA, ADB-CHMINACA, 5F-MDMB-PINACA and 
CUMYL-4CN-BINACA conducted by the EMCDDA
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I  New challenges, new responses
I Strengthening early warning and response
The rapidly changing nature of the market in new 
substances, its growing links with the established illicit 
market and the large total number of substances that need 
to be monitored present challenges for early warning 
activities. In response to this, the EMCDDA has undertaken 
a rolling programme of work to strengthen early warning 
and response activities in order to better protect public 
health. This includes developing a range of interconnected 
systems as part of the EU Early Warning System — 
including a toxicovigilance system, signal management 
system, open source information monitoring system and 
risk communication system — that allows it to better 
identify, understand, prioritise and respond to public 
health threats. The foundation of the system continues to 
be the chemical identification of new substances in 
seizures made by law enforcement and in poisoning cases. 
In addition, the EMCDDA has also conducted an increasing 
number of risk assessments on substances causing 
particular concern to the European Union.
The toxicovigilance system allows the EMCDDA to identify, 
manage, understand and, through other components of 
the EU Early Warning System and risk assessment 
process, react to serious adverse events associated with 
new substances. Much of the initial work has focused on 
strengthening the detection, reporting and assessment of 
such events reported by the countries which are part of 
the EU Early Warning System, as well as those events 
identified by the EMCDDA from the scientific and medical 
literature and other open sources. The signal management 
system provides a framework for identifying, understanding 
and prioritising threats related to new substances. 
It is clear from recent developments that the early 
identification and response to emerging threats can be 
strengthened by proactive data collection systems working 
alongside existing reporting systems. As a result, the 
EMCDDA is working to improve the ability of the EU Early 
Warning System to detect signals of public health 
relevance from open source information by developing a 
monitoring system that can provide new data on areas 
such as the online drug markets, epidemiology and reports 
of serious adverse events. The EMCDDA has also looked at 
ways to improve risk communication related to threats and 
other important signals identified through its early warning 
and risk assessment activities. This work is intended to 
support the work of the EU Early Warning System’s 
network, including strengthening national preparedness. 
At EU level, the legal framework for responding to public 
health and social threats caused by new psychoactive 
substances, which dated from 2005, has been revised, 
with the aim of establishing a swifter, more effective 
system. The new legislation retains the three-step 
approach of early warning, risk assessment and control 
measures, while strengthening existing processes by 
streamlining and accelerating data collection and 
assessment procedures, and introducing shorter deadlines 
(European Parliament and Council, 2017a,b).
The EMCDDA has also further strengthened its 
cooperation with United Nations agencies. In particular, 
over the past few years the EMCDDA has provided data, 
analysis and expertise to the World Health Organization 
(WHO) and United Nations Office on Drugs and Crime 
(UNODC) in order to inform the global response to this 
issue and ultimately help protect public health. Reflecting 
current concerns, one focus of this work has been on new 
synthetic opioids, and particularly the fentanils.
I Discussion and conclusion
Over the last decade, there has been a large increase in 
new psychoactive substances in Europe. As a result, there 
have also been large increases in seizures reported by law 
enforcement as well as severe poisonings, deaths and 
other types of harms. As the range of substances and 
products has grown, groups of consumers have also 
diversified. There are also growing interactions between 
the market in new substances and illicit drugs, as new 
Unknown to users, synthetic cannabinoids have also 
been sold as ecstasy/MDMA and other illicit drugs. In 
some cases, this has led to severe poisoning (Allibe 
et al., 2016; Brenneman et al., 2016; Pap, 2016).
Potent opioids have also been identified in smoking 
mixtures sold in Europe, which users will often be 
unaware of. These include O-desmethyltramadol, 
U-47,700 and furanylfentanyl (Coopman and 
Cordonnier, 2017; Dresen et al., 2010; EMCDDA, 
2017c). Using these types of products could cause 
life-threatening poisoning. This risk will be especially 
high in people with no tolerance to opioids.
Other risks related to synthetic 
cannabinoids and smoking mixtures
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substances are increasingly sold directly on the illicit drug 
market under their own names or passed off as illicit drugs 
to unsuspecting users. This includes feeding the illicit 
market when established drugs are in short supply. 
A particular challenge here is the new opioids, especially 
the highly potent fentanils, which may enter the heroin/
illicit opioid supply chain.
A number of positive developments have been reported in 
the past few years, such as a drop in the number of new 
substances identified for the first time in 2016 and 2017. 
As noted, in part, this may reflect the results of sustained 
efforts to control new substances in Europe, including their 
open sale as ‘legal highs’ on the high street, which will 
have a knock-on effect on the demand from retailers. While 
analysis of this issue is limited, it has been suggested that 
these approaches may have led producers and retailers in 
Europe to drop out of the market. Like most phenomena, 
part of the market is likely to have been driven by fads, with 
enthusiasm waning over time. It is possible that some 
individuals became involved in the market only because 
products were widely available and they saw an 
opportunity to make money quickly and easily. These 
suggestions are certainly worth further study in order to 
better understand the effects of regulation and how 
markets respond. Similarly, changes in the established 
illicit market can also have an impact on demand for some 
new substances. Has the recent rebound in the MDMA 
market in Europe affected demand for new cathinones and 
phenethylamines (EMCDDA, 2016b)?
Despite these gains, new challenges have also emerged. 
The recent large increase in new opioids detected in 
Europe — particularly the 28 fentanils since 2012 — is a 
major concern because of the severe risk of fatal poisoning 
that they pose. Adding to this problem are the two additional 
fentanils that have been reported as of February 2018.  
More broadly, the general trend towards highly potent 
substances is worrying, not only because they pose a 
greater risk of severe poisoning, but also because they are 
easier to conceal and smuggle. A few grams are often 
sufficient to make many thousands of doses for the drug 
market, and can be easily concealed in a small package. 
This can make it harder for customs and border forces to 
detect and intercept them at borders. As the volume of 
express mail continues to increase, without new 
approaches, the detection of such packages may become 
increasingly difficult. Given the globalised nature of the 
market, these types of substances can present a serious 
cross-border threat to health. As highlighted in this report, 
the synthetic opioids and synthetic cannabinoids are two 
groups that already particularly stand out in this respect. 
While the explosive outbreaks reported in the United 
States and Canada caused by these substances has been 
limited in Europe so far, there is little room for 
complacency. Recently, clusters and outbreaks of 
overdoses involving the fentanils have increased in some 
parts of Europe. However, little is certain in this complex 
market. Reflecting its globalised nature, it is unclear what 
the impact will be on the availability of fentanils in Europe 
as a result of the recent generic control measures 
introduced for this family of substances in the United 
States during February 2018 (United States Department of 
Justice, 2018).
While growth of the market at a similar pace to that seen 
since 2008 is not inevitable, the examples provided in this 
report highlight that the continued availability of new 
psychoactive substances is introducing greater complexity 
into the drug situation. They also serve to underline the 
importance of continued investment in strong early 
warning systems at both national and EU levels, as well as 
a more rapid risk assessment process at EU level in order 
to protect the health and security of people living in 
Europe. The new European Union legislative framework on 
new psychoactive substances will play a central role in 
helping achieve these aims.
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